RALLYBIO CORPORATION Capital Expenditures Incurred but Not yet Paid
RALLYBIO CORPORATION (RLYB) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-11-07
- RALLYBIO CORPORATION capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was $12.00K.
- RALLYBIO CORPORATION capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was $0.00.
- RALLYBIO CORPORATION capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $0.00.
- RALLYBIO CORPORATION capital expenditures incurred but not yet paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- RALLYBIO CORPORATION capital expenditures incurred but not yet paid for fiscal 2021 was $13.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |||
| 2023-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $12.00K derived: sum of 2 quarters · filed 2024-11-07 | $12.00K 10-Q · filed 2024-11-07 | $12.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2023-08-08 | -$6.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-05-09 | -$6.00K derived: sum of 3 quarters · filed 2023-11-09 | -$8.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$6.00K derived: sum of 2 quarters · filed 2023-11-09 | -$8.00K derived: sum of 3 quarters · filed 2023-11-09 | $0.00 10-K · filed 2023-03-06 |
| 2022-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$8.00K derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | -$23.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.00K 10-Q · filed 2023-08-08 | -$17.00K derived: sum of 3 quarters · filed 2023-08-08 | $4.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $8.00K 10-Q · filed 2023-05-09 | -$15.00K derived: sum of 2 quarters · filed 2023-05-09 | $6.00K derived: sum of 3 quarters · filed 2023-05-09 | $21.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$2.00K derived: sum of 2 quarters · filed 2023-03-06 | $13.00K derived: sum of 3 quarters · filed 2023-03-06 | $13.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $36.00K derived: sum of 2 quarters · filed 2022-11-07 | $36.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $15.00K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $6.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $6.00K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |